| Date Filed | Type | Description |
| 03/26/2020 |
8-K
| Quarterly results |
| 03/05/2020 |
10-Q
| Quarterly Report for the period ended January 31, 2020 |
| 03/05/2020 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 03/03/2020 |
GN
| Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer |
| 02/12/2020 |
SC 13G/A
| DIMENSIONAL FUND ADVISORS LP reports a 5.6% stake in RAFAEL HOLDINGS INC-CLASS B |
| 02/04/2020 |
8-K
| Other Events |
| 01/28/2020 |
4
| ASH MENACHEM (President) has filed a Form 4 on Rafael Holdings, Inc.|
Txns:
| Paid exercise price by delivering 5,238 shares
@ $22.155, valued at
$116k
|
|
| 01/21/2020 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 01/14/2020 |
GN
| Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) for Patients with Metastatic Pancreatic Cancer |
| 01/13/2020 |
GN
| Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference |
| 01/06/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/06/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/06/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/10/2019 |
8-K
| Quarterly results |
| 12/09/2019 |
10-Q
| Quarterly Report for the period ended October 31, 2019 |
| 12/09/2019 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 12/03/2019 |
GN
| Data on Rafael Pharmaceuticals' CPI-613® (devimistat) in Patients with Relapsed Burkitt Lymphoma to be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition |
| 12/03/2019 |
GN
| Timothy Pardee, M.D., Ph.D., Co-Chief Medical Officer of Rafael Pharmaceuticals, to Present on CPI-613® (devimistat) in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting & Expos |
| 12/02/2019 |
25
| Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities: |
| 12/02/2019 |
GN
| Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt's Lymphoma/Leukemia to Massachusetts General Hospital in Boston |
| 11/21/2019 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/18/2019 |
CERT
| Form CERT - |
| 11/18/2019 |
8-A12B
| Form 8-A12B - Registration of securities [Section 12(b)]: |
| 11/18/2019 |
8-K
| Quarterly results |
| 10/30/2019 |
GN
| Rafael Pharmaceuticals Appoints Chief Medical Officer, José Octávio Costa Filho, M.D. |
| 10/24/2019 |
GN
| Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer |
| 10/04/2019 |
10-K
| Annual Report for the period ended July 31, 2019 |
| 10/03/2019 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 10/02/2019 |
GN
| Rafael Pharmaceuticals Appoints Wendy McDermott to Chief People Officer |
| 09/26/2019 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 09/24/2019 |
4
| Polinsky David (CFO) has filed a Form 4 on Rafael Holdings, Inc.|
Txns:
| Granted 5,000 shares
@ $0 |
|
| 09/19/2019 |
GN
| Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| 09/16/2019 |
GN
| Peer-Reviewed Journal Future Oncology Publishes Two Manuscripts on Cancer Metabolism and Drug Candidate CPI-613® (Devimistat) |
| 08/08/2019 |
8-K
| Unregistered Sales of Equity Securities |
|